Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Renovaro Inc. - Common Stock
(NQ:
RENB
)
0.6482
+0.0153 (+2.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renovaro Inc. - Common Stock
< Previous
1
2
3
Next >
Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD
January 16, 2024
Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
Fruit Fly Study Opens Door to Novel Immunotherapy Approach Against Cancer
January 12, 2024
Via
Investor Brand Network
RENOVARO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Renovaro Biosciences Inc. - RENB
January 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Study Shows Ongoing Benefits Once Immunotherapy Stops
January 02, 2024
Via
Investor Brand Network
Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes
December 19, 2023
Via
Investor Brand Network
Researchers Harnessing Immune System to Fight Cancer More Effectively
December 07, 2023
Via
Investor Brand Network
Study Says Patients on Gene Therapy Need Long-Term Monitoring
November 27, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview
November 22, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases, Harness Cutting-Edge AI Technology
November 21, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Opportunity in Largely Untapped Precision Medicine Market
November 17, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
How Immunotherapy Is Cementing a Role in Cancer Treatment
November 13, 2023
Via
Investor Brand Network
Renovaro Biosciences Inc. (NASDAQ: RENB) CEO Provides Update on Combination with AI Expert GEDiCube Intl Ltd. in Letter to Shareholders
November 10, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics
November 08, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced
November 06, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Derivatives
Exposures
Artificial Intelligence
Derivatives
Alarming Data Highlights Gaps in Treating People with Chronic HBV
November 01, 2023
Via
Investor Brand Network
Biotech Firms Register Successes in Quest for Better Pancreatic Cancer Treatments
October 26, 2023
Via
Investor Brand Network
Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine
October 23, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Scientists Find Potential to Reverse Prostate Cancer Treatment Resistance
October 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech
October 20, 2023
Via
Investor Brand Network
Everything You Need to Know About Nonreactive Hep B Screening Results
October 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Appoints Intel Capital Cofounder to Board
October 11, 2023
Via
Investor Brand Network
Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors
October 11, 2023
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
Patients with Metastatic Solid Tumors Have Better Outcomes After Prophylactic Radiation, Study Finds
October 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Strategic Board Appointments of Two Finance Industry Experts
October 10, 2023
Via
Investor Brand Network
Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors
October 10, 2023
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
RENOVARO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Renovaro Biosciences Inc. - RENB
October 05, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
New Prediction Model Could Slash Unnecessary Pancreatic Cancer Biopsies
October 04, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company
October 02, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD
October 02, 2023
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine
From
Renovaro Biosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.